{"id":3391,"date":"2021-07-29T16:15:00","date_gmt":"2021-07-29T23:15:00","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=3391"},"modified":"2022-08-16T14:13:42","modified_gmt":"2022-08-16T21:13:42","slug":"sglt2-inhibitor-adds-years-of-life-to-patients-with-heart-failure","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2021\/07\/29\/sglt2-inhibitor-adds-years-of-life-to-patients-with-heart-failure\/","title":{"rendered":"SGLT2 Inhibitor Adds Years of Life to Patients With Heart Failure"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"3391\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<p>&#8220;Patients with heart failure with reduced ejection fraction (HFrEF) may increase their lifespan if they take the SGLT2 inhibitor dapagliflozin (Farxiga) over the long term, a statistical modeling study showed.<\/p>\n\n\n\n<p>Mean event-free survival was an estimated 8.3 years in a patient with HFrEF who started dapagliflozin at age 65. As a similar patient on standard therapy alone would only be expected to live free from heart failure events for another 6.2 years, this represented an event-free survival time gain of 2.1 years (<em>P<\/em>=0.002).&#8221;<br><br>Learn more, <a href=\"https:\/\/www.medpagetoday.com\/cardiology\/prevention\/93788?xid=nl_mpt_DHE_2021-07-29&amp;eun=g1917319d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-07-29&amp;utm_term=NL_Daily_DHE_dual-gmail-definition\">here<\/a>.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"3391\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading &#8220;Patients with heart failure with reduced ejection fraction (HFrEF) may increase their lifespan if they take the SGLT2 inhibitor dapagliflozin (Farxiga) over the long term, a statistical modeling study &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2021\/07\/29\/sglt2-inhibitor-adds-years-of-life-to-patients-with-heart-failure\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SGLT2 Inhibitor Adds Years of Life to Patients With Heart Failure&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1135,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[45,912,5],"tags":[192],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"0","views":"1524","post_likes_plusCounter":"1","post_dislikes_plusCounter":"1","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3391"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=3391"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3391\/revisions"}],"predecessor-version":[{"id":3392,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/3391\/revisions\/3392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/1135"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=3391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=3391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=3391"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=3391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}